Physician-diagnosed early-stage knee osteoarthritis (Kellgren Lawrence grade II).Chronic knee pain persisting for a minimum of three months. A (WOMAC) pain subscale score more than 40 . early osteoarthritis
Conditions
Interventions
Autologous adipose-derived stem cells 50M Cells in 3 ml,Hyaluronic Acid 2 ml
Osnozel,Hyaluronic Acid
Sponsors
Medeze Group PCL
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 40 and 80 years. 2.Clinically diagnosed with early-stage osteoarthritis of the knee, specifically Kellgren-Lawrence (K-L) grade II, by a physician. 3.Presence of chronic knee pain for a minimum duration of 3 months. 4.Baseline WOMAC pain score greater than or equal to 40 (on a 0-100 scale). 5.Body Mass Index (BMI) less than 30 kg/m2. 6.Willingness to participate and provision of written informed consent. 7.Ability to comply with the scheduled follow-up visits. 8.General health status deemed suitable for study participation, as determined by the investigating physician. 9.Thai nationality, currently residing in Bangkok.
Exclusion criteria
Exclusion criteria: 1.History of knee surgery or receiving intra-articular injections within the preceding six months. 2.Diagnosis of other inflammatory or systemic arthropathies, such as rheumatoid arthritis (RA), gout, or Systemic Lupus Erythematosus (SLE). 3.Presence of septic arthritis or a prior history of joint infection. 4.Current use of anticoagulant medication that cannot be discontinued, or a pre-existing bleeding disorder. 5.Presence of any significant chronic systemic disease (comorbidities). 6.Pregnancy or lactation (breastfeeding). 7.Presence of a psychiatric disorder that compromises the ability to provide informed consent. 8.Participation in any other clinical trial within three months prior to enrollment. 9.Known allergy or hypersensitivity to the therapeutic agents (e.g., Hyaluronic Acid (HA)) or local anesthetics. 10.Considered unsuitable for participation by the investigator due to health or ethical concerns.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Osteoartritis 2 weeks, 1, 3, and 6 months. WOMAC Score | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain 2 weeks, 1, 3, and 6 months. Visual Analog Scale,Knee injury or osteoarthritis 2 weeks, 1, 3, and 6 months. Knee injury and Osteoarthritis Outcome Score | — |
Countries
Thailand
Contacts
Public ContactDr.Pornthep Tangkanchanavekul
Faculty of Medicine, Suranaree University of Technology
Outcome results
None listed